K. O’Reilly

发表

Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia.

S. Chadda, S. Ralston, R. Bosshard, 2018, Cancer treatment reviews.

A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model

F. Scolari, R. Sandford, G. Walz, 2018, BMC Nephrology.

Caregiver burden in cystic fibrosis: a systematic literature review

L. Longworth, G. Vega-Hernandez, Conor Daly, 2022, Therapeutic advances in respiratory disease.

The burden of illness in patients with hyponatraemia in Sweden: a population‐based registry study

P. Sobocki, P. Robinson, M. Gisby, 2016, International journal of clinical practice.

A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease

Paul Robinson, P. Robinson, Claire Woon, 2015, BMC Nephrology.

A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta‐analysis of the vaptans

J. Glanville, A. Peri, I. Cranston, 2017, Clinical endocrinology.

Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden

D. Trueman, P. Robinson, M. Gisby, 2016, BMC Endocrine Disorders.

The Cost-Effectiveness of Tolvaptan for the Treatment of Hyponatraemia Secondary To Syndrome Of Inappropriate Antidiuretic Hormone Secretion in Sweden.

D. Trueman, P. Robinson, J. Lundberg, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model

P. McEwan, K. O'reilly, H. Bennett, 2019, BMC Nephrology.

Rationale and study protocol of ACQUIRE, a prospective, observational study measuring quality of life, treatment preference and treatment satisfaction of autosomal dominant polycystic kidney disease (ADPKD) patients in Europe

H. Doll, D. Joly, J. Quinn, 2020, BMC Nephrology.

EQ-5D Scores In Patients Receiving Tolvaptan for the Treatment Of Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.

D. Trueman, P. Robinson, E. Hancock, 2014, Value in Health.

The Cost-Effectiveness of Tolvaptan for the Treatment of Hyponatraemia Secondary To Syndrome Of Inappropriate Antidiuretic Hormone Secretion in Sweden.

D. Trueman, P. Robinson, J. Lundberg, 2014, Value in Health.